Search

everythinglearnresearchcommunity

for

Search:↓

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

The combination therapy significantly improved Riehl’s melanosis in patients without serious side effects.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Bimekizumab effectively treated a man's chronic beard hair loss.

Brodalumab is more effective than ustekinumab for treating psoriasis.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.

Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Individualized treatments may help manage Dercum's disease symptoms.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Dupilumab effectively controls symptoms in infants with Netherton syndrome.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.

Brodalumab is more effective than ustekinumab in treating psoriasis.

Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

Rituximab may cause skin issues, but baricitinib can help improve them.

Mogamulizumab can cause hair loss, often linked to a better treatment response.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.